Swiss agree to extradite Chinese researcher in US corporate espionage case
This content was published on
2 minutes
The Swiss Federal Office of Justice (FOJ)External link has approved the extradition of a Chinese researcher to the United States. Gongda Xue is charged with using trade secrets stolen from a factory of the British pharmaceutical group GlaxoSmithKline (GSK).
The decision was taken on July 12, from which date the researcher has 30 days to appeal to the Federal Criminal Court, a spokeswoman for the FOJ told the French news agency, AFP, on Tuesday.
Gongda Xue is the brother of Yu Xue, a Chinese-American biochemist who pleaded guilty last year at a US District Court in Pennsylvania to stealing trade secrets on GSK’s work in the biopharmaceutical sector, including the treatment of cancer and other serious diseases.
A total of five people were charged in the case, three of whom formed a company in China called Renopharma to sell the stolen trade secrets.
Yu Xue, who worked for GSK from 2006 to 2016, had been presented by the American courts as one of the “leading protein biochemists in the world”.
According to a spokeswoman for the Friedrich Miescher Institute for Biomedical Research, Gongda Xue worked there “as a postdoctoral fellow from 2008 to 2014”.
The US Department of Justice last year called the case an “economic war”, claiming that Renopharma, based in Nanjing, China, is “financed by the Chinese government”.
Popular Stories
More
Foreign affairs
European nations snub Swiss-made weapons over Ukraine restrictions
Switzerland will deliver rubble removal equipment to Ukraine
This content was published on
Thirty rubble removal machines and thirty fire-fighting pumps: this is the equipment that Switzerland will be delivering to the Ukraine in the next few days. The total value of these goods is 5.6 million Swiss francs.
A third of Swiss residents plan to change health insurers
This content was published on
After the announced sharp increase in premiums for 2025, about one in three people would be considering changing health insurance companies.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Swiss firms in record number of mergers and acquisitions
This content was published on
The number of merger and acquisition deals involving Swiss companies hit a record high in 2018, according to a report by consultancy firm KPMG.
This content was published on
In recent days, Johnson & Johnson has been urged to review its sprawling portfolio that ranges from baby oil to cancer drugs, and there were questions for Novartis over the future of its struggling eyecare business. This week, Pfizer will update shareholders on plans for a potential break-up, while GlaxoSmithKline is likely to be pressed…
Chinese researcher in ‘economic warfare’ case loses appeal
This content was published on
A Chinese scientist, accused by the US of helping to steal trade secrets, must remain in Swiss custody due to flight risk, says a federal court.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.